Panthera Biopartners launches, announces first trial site with plan for execs, expansion

 Why wearables, health records and clinical trials need a blockchain injection
More trials are on the horizon for Panthera Biopartners, with a CEO set to be named soon. (peshkov/iStockPhoto)

Independent site management organization (SMO) Panthera Biopartners has kick-started its first clinical trial in the U.K., officially launching as it looks to tap a C-suite team and raise cash.  

The first clinical trial site starts in the north of England, with three “trials already in the pipeline,” the SMO says in an email to FierceCRO.

“At least three further sites to open in the U.K. in 2020,” the company adds, as it looks to shortly announce a new CEO and other high-up appointments and is “in discussions on international expansion” outside of the U.K.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Dr. Ian Smith, founder of Synexus, one of the world’s largest SMOs, is also one of the founders of Panthera alongside Professor John Lyon, who was previously a global executive in CRO Covance (now LabCorp) and a serial entrepreneur. The company is currently raising its A round, “which will be concluded shortly,” the company says.

SMOs essentially implement trials on behalf of clients, from CROs to pharma and biotech companies.

Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas that are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis, diabetes, etc. In the new year, the company is looking at nonalcoholic steatohepatitis in primary care and oncology and neurology for secondary care.

Smith said: “It has been so encouraging talking to CROs and major pharma companies. They have really welcomed the entry of Panthera Biopartners as an independent SMO which incorporates new technology into the running of clinical trials and the recruitment of patients.

“We plan to have a number of sites up and running by the first quarter of 2020 with an ongoing expansion program across the UK and overseas.”

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.